The Next Frontier in Heart Failure Treatment
Cardiac Success is developing the V-sling device to improve the lives of the millions of patients who, despite guidance-directed medical therapy, continue to suffer and deteriorate from Heart Failure with Reduced Ejection Fraction (HFrEF). The V-sling is a transcatheter ventricular repair device designed based on a successful surgical papillary muscle approximation procedure.
Ventricular Repair Device Treating
Heart Failure with Left Ventricle Dilation
There are currently about 8 million heart failure patients worldwide whose lives could potentially be improved by treatment with the V-sling device. Cardiac Success aims to treat patients suffering from HFrEF (Heart Failure with reduced Ejection Fraction), a condition typically associated with ventricular dilation, papillary muscle dislocation, and low ejection fraction.
The V-sling is a transcatheter ventricular repair device designed based on a successful surgical papillary muscle approximation procedure.
V-Sling Unique Benefits
Restores the conical shape of the Left Ventricle
Eliminates leaflet tethering
Adjustable implant size for optimized Left Ventricle repair
Safe anchorless implant, no endocardium penetration
Does not block future interventions
Israeli Medical Device Startup, Cardiac Success Ltd.,
Closes US $5.2M Series A Financing.
The round was led by 415 CAPITAL, a specialist medical technology venture capital firm who was joined by an unnamed strategic investor and global leader in structural heart interventions. Proceeds will be used for pre-clinical testing and the completion of a First-in-Human trial of the company’s innovative “V-sling” heart failure therapy.
Cardiac Success Awarded €10M in Grants and Equity Investment from the European Innovation Council
Funds to accelerate the clinical development of the novel “V-sling” system, a transcatheter ventricular repair implant designed to provide a new therapy for heart failure patients.
Experienced R&D leader in start-ups and at large medical device companies. Previously leader of the promising Mitral program in Edwards Lifesciences, the Sapien M3
David Neustadter, PhD
CTO & Founder
Over 20 years experience in medical device design. Co-founder, CTO and VP R&D in 2 previous medical device startup companies.
Dr. Shimon Eckhouse
Chairman & Co-Founder
An inventor, active entrepreneur and investor in MedTech companies. Former chairman and co-founder of Syneron Medical (acquired by APAX), founder, chairman and CEO of Lumenis and co-founder of Ventor (acquired by Medtronic).
Lea Waisman Shaler,
15 years of experience in design, development, and management of R&D projects in interventional cardiology and gastroenterology.
Prof. Rafael Beyar
Interventional cardiologist, an established entrepreneur, former director and CEO of Rambam Medical Center. Successfully founded and sold 2 major cardiovascular companies.
This project has received funding from the European Union’s Horizon Europe under grant agreement